dc.contributor.author | Mulla, K | |
dc.contributor.author | Farag, S | |
dc.contributor.author | Moore, B | |
dc.contributor.author | Matharu, S | |
dc.contributor.author | Young, K | |
dc.contributor.author | Larkin, J | |
dc.contributor.author | Popat, S | |
dc.contributor.author | Morganstein, DL | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2023-05-02T09:29:28Z | |
dc.date.available | 2023-05-02T09:29:28Z | |
dc.date.issued | 2023-04-01 | |
dc.identifier.citation | Diabetic Medicine, 2023, 40 (4), pp. e15053 - | en_US |
dc.identifier.issn | 0742-3071 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5772 | |
dc.identifier.eissn | 1464-5491 | |
dc.identifier.eissn | 1464-5491 | |
dc.identifier.doi | 10.1111/dme.15053 | |
dc.description.abstract | AIMS: We systematically studied the presence of hyperglycaemia during treatment with Immune Checkpoint Inhibitors (ICPI) for cancer, in those with and without diabetes at baseline, and determined the cause of new-onset hyperglycaemia, METHODS: Retrospective review of electronic records of those receiving an ICPI for melanoma, lung or renal cancer. RESULTS: Overall, 959 participants were included. In this study, 103 had diabetes at baseline (10.7%). Those with lung cancer had the highest frequency of diabetes; 131 people had hyperglycaemia (defined as at least one glucose ≥11.1 mmol/L) in the year after starting an ICPI. The incidence was 55% in those with diabetes at baseline, and 8.6% in those without baseline diabetes. Among 74 with new-onset hyperglycaemia (without pre-existing diabetes) 76% was attributable to steroid induced diabetes, with 9.5% due to ICPI Induced diabetes resembling type 1 diabetes. CONCLUSIONS: Hyperglycaemia is common in persons receiving an ICPI for cancer, including 8.6% of those without known diabetes. While much of this is due to glucocorticoid use, care is needed to avoid missing those with ICPI-induced diabetes who are at risk of diabetic ketoacidosis, which is a medical emergency. | |
dc.format | Print-Electronic | |
dc.format.extent | e15053 - | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | WILEY | en_US |
dc.relation.ispartof | Diabetic Medicine | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0 | en_US |
dc.subject | cancer | |
dc.subject | clinical diabetes | |
dc.subject | Humans | |
dc.subject | Hyperglycemia | |
dc.subject | Immune Checkpoint Inhibitors | |
dc.subject | Incidence | |
dc.subject | Diabetes Mellitus, Type 1 | |
dc.subject | Lung Neoplasms | |
dc.title | Hyperglycaemia following immune checkpoint inhibitor therapy-Incidence, aetiology and assessment. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2023-01-23 | |
dc.date.updated | 2023-05-02T09:28:58Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1111/dme.15053 | en_US |
rioxxterms.licenseref.startdate | 2023-04-01 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/36696014 | |
pubs.issue | 4 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.) | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.1111/dme.15053 | |
pubs.volume | 40 | |
dc.contributor.icrauthor | Popat, Sanjay | |
icr.provenance | Deposited by Mr Arek Surman (impersonating Prof Robert Huddart) on 2023-05-02. Deposit type is initial. No. of files: 1. Files: Diabetic Medicine - 2023 - Mulla - Hyperglycaemia following immune checkpoint inhibitor therapy Incidence aetiology and.pdf | |